Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Lymphocyte antigen 6 complex locus C1 (Ly6C) is a GPI-anchored cell-surface protein encoded by the Ly6c1 gene in mice. It belongs to the Ly6/uPAR superfamily, characterized by a conserved LU domain with multiple cysteine residues forming disulfide bridges and a “three-finger” protein topology similar to snake venom neurotoxins[5]. Ly6C is used extensively as a cell surface marker to distinguish subsets of immune cells, especially monocytes, T cells, and dendritic cells. High Ly6C expression (Ly6C^hi) marks pro-inflammatory monocytes, while low Ly6C (Ly6C^lo) defines patrolling monocytes. Ly6C is also expressed on subsets of memory CD8+ T cells and is upregulated during inflammation. Its main utility is in murine immunology and preclinical disease models for cell tracking and functional assays but it is not a druggable human therapeutic target[5][6][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Lymphocyte antigen 6 complex locus C1 (Ly6C).